{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:28:22Z","timestamp":1791102502582,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,12,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Final results are presented from two consecutive European studies for patients with metastatic rhabdomyosarcoma (RMS) to identify prognostic variables and determine the value of high-dose chemotherapy (HDCT) in complete remission. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> A total of 174 patients aged 3 months to 18 years participated. From 1989 to 1991, patients received four cycles of intensive multiagent chemotherapy. From 1991 to 1995, patients achieving complete remission received consolidation with HDCT. All received local therapy (surgery, radiation therapy) according to response. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> At a median follow-up of 8 years, 5-year overall survival (OS) and event-free survival (EFS) for the whole group were 24% and 20%, respectively. No statistical difference was found between HDCT and standard chemotherapy (5-year OS, 36% v 27%; EFS 29% v 23%). Univariate analysis identified primary tumor in parameningeal, extremity, or other sites; age younger than 1 year and older than 10 years; bone or bone marrow metastases; multiple metastases; and multiple sites of metastases as unfavorable prognostic factors for OS and EFS. Multivariate analysis identified unfavorable site, bone or bone marrow involvement, and unfavorable age as independently unfavorable factors. Two subgroups were identified. Those with fewer than two unfavorable factors had 5-year EFS and OS of 40% and 47%, respectively. Patients with \u2265 two unfavorable factors had 5-year EFS and OS of 7.5% and 9%, respectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> A minority of patients with metastatic RMS have better survival than overall results for this population suggest. Those in the highest risk group have such poor survival that they are candidates for first-line novel therapies. There is no evidence that consolidation with HDCT improves outcome. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.04.083","type":"journal-article","created":{"date-parts":[[2004,11,30]],"date-time":"2004-11-30T00:08:02Z","timestamp":1101773282000},"page":"4787-4794","source":"Crossref","is-referenced-by-count":146,"title":["European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic Factors"],"prefix":"10.1200","volume":"22","author":[{"given":"M.","family":"Carli","sequence":"first","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Colombatti","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Oberlin","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bisogno","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Treuner","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Koscielniak","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tridello","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garaventa","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pinkerton","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stevens","sequence":"additional","affiliation":[{"name":"From the University of Padova, Padova; Institut \u201cG. Gaslini,\u201d Genova, Italy; Institut Gustave Roussy, Villejuif, France; Olgahospital, Stuttgart, Germany; Mater Hospitals, Brisbane, Australia; and University of Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102143240706"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.443"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.610"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950200305"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2796"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Frascella E, Pritchard-Jones K, Modak S, et al: Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin, vincristine. Eur J Cancer 32A:821,1996\u2013825,","DOI":"10.1016\/0959-8049(95)00665-6"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R11","unstructured":"Cox DR, Oakes D: Analysis of Survival Data . London, United Kingdom, Chapman and Hall, 1992"},{"key":"R12","unstructured":"Pearson ES, Hartley HO: Biometrika Tables for Statisticians . Cambridge, United Kingdom, Cambridge University Press, 1966"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1227"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.129"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200001)34:1<29::AID-MPO6>3.0.CO;2-7"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3468(90)90228-2"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950220105"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00155-X"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700628"},{"key":"R20","unstructured":"Malagolowkin MH, Sposto R, Grovas L, et al: Lack of improvement in survival of children with metastatic rhabdomyosarcoma (RMS) treated with intensive therapy followed by stem cell transplant (SCT) for control of minimal residual disease. Proc Am Soc Clin Oncol 18:555,1999,  (abstr 2143)"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199902)32:2<88::AID-MPO3>3.0.CO;2-N"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1697"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190204"},{"key":"R24","unstructured":"Raney RB Jr, Gehan EA, Maurer HM, et al: Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV): The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group. Cancer Clin Trials 2:19,1979\u201328,"},{"key":"R25","unstructured":"Anderson JR, Ruby E, Lin M, et al: Identification of a favorable subset of patients (PTS) with metastatic (MET) rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 16:510,1997,  (abstr 1836)"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.10441"},{"key":"R27","unstructured":"Carli M, Colombatti R, Pinkerton R, et al: Prognostic factors in children with metastatic rhabdomyosarcoma: Results of the European Intergroup Studies (EIS) MMT'89 and MMT'91. Proc SIOP Med Pediatr Oncol 29: 324,1997,  (abstr 0-32)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.04.083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:23:53Z","timestamp":1653510233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.04.083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,1]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2004,12,1]]}},"alternative-id":["10.1200\/JCO.2004.04.083"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.04.083","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,1]]}}}